Intent: Discussion and sharing of information relating to the geopolitical situation, specifically concerns surrounding the imposition of trade tariffs by the US. Understanding of the industry case for altering Ireland's position in the European Council relating to the GPL, as well as raising potential subjects for Ireland's EU Presidency agenda.
Details: IPHA Delegation to meet with An Tánaiste on EU health legislation and policy matters (including GPL and Ireland's EU Presidency), as well as the domestic issue of the negotiation of the pricing and supply agreement.
Intent: (a) Request to Irish Government to take account of the competitiveness of the pharmaceutical industry in Europe and not there dilute or reduce RDP. (b) Take account of the importance of the pharmaceutical industry in competitiveness of EU.
Details: (i) EU General Pharmaceutical Legislation and Irish Government position on Intellectual Property Rights. (ii) EU and Irish competitiveness and the pharmaceutical industry.
Intent: Highlight the impact of US tariffs and trade uncertainty on the export focussed Irish drinks manufacturing sector and the need for Government actions to support the sector including removal of tariffs, market diversification supports and deferral of impending alcohol labelling legislation
Intent: (i) The medicines reimbursement system should be designed and resourced to comply with the 2013 Health Act required for HSE decisions within 180 days excluding clock stops. (ii) Request for meeting to discuss IPHA proposals to address delays in the reimbursement system. (iii) Request to present IPHA Timeline data to the Oireachtas Health Committee.
Details: Future Framework Agreement - issues concerning timely reimbursement of medicines in Ireland.
Intent: (i) The medicines reimbursement system should be designed and resourced to comply with the 2013 Health Act required for HSE decisions within 180 days excluding clock stops. (ii) Request for meeting to discuss IPHA proposals to address delays in the reimbursement system. (iii) Request to present IPHA Timeline data to the Oireachtas Health Committee.
Details: Future Framework Agreement - issues concerning timely reimbursement of medicines in Ireland.
Intent: (i) Ireland to advocate for no tariffs on medicines from US, and in the event of such, no reciprocal tariffs by the EU on medicines. (ii) Response to US s.232 process should position Ireland as a reliable supply chain partner, part of 'friends and allies of the US' to avoid tariffs on medicines.
Intent: (i) Ireland to advocate for no tariffs on medicines from US, and in the event of such, no reciprocal tariffs by the EU on medicines. (ii) Response to US s.232 process should position Ireland as a reliable supply chain partner, part of 'friends and allies of the US' to avoid tariffs on medicines.
